NCT00985569

Brief Summary

The purpose is to assess the efficacy, clinical outcomes, and potential Quality Indicator benefits associated with the use of Lubiprostone in nursing home residents with a confirmed diagnosis of chronic idiopathic constipation.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
105

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2009

Shorter than P25 for all trials

Geographic Reach
1 country

3 active sites

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 24, 2009

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 28, 2009

Completed
1 month until next milestone

Study Start

First participant enrolled

November 1, 2009

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2010

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2010

Completed
Last Updated

November 23, 2010

Status Verified

November 1, 2010

Enrollment Period

5 months

First QC Date

September 24, 2009

Last Update Submit

November 22, 2010

Conditions

Keywords

ConstipationNursing HomeQuality Indicator

Outcome Measures

Primary Outcomes (1)

  • To determine the overall reduction in the number of oral medicines taken by each NH resident at enrollment and at 60 days.

    60 days

Secondary Outcomes (3)

  • Reduce the number of oral medicines being taken by any nursing home resident from 9 or more to fewer than 9. (Quality Indicator Number 6)

    60 days

  • To compare the occurrence of fecal impaction during a 60-day period prior to initiating Lubiprostone with a 60 day period after initiating Lubiprostone. (Quality Indicator Number 11)

    60 days

  • To compare the occurrence of fecal incontinence during a 60-day period prior to initiating Lubiprostone with a 60 day period after initiating Lubiprostone.

    60 days

Study Arms (1)

Lubiprostone

Subjects switching from current bowel medicines to lubiprostone

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Nursing Home Residents (adult subjects living in Nursing Homes)

You may qualify if:

  • Patients must meet all of the following criteria to be eligible for the study:
  • Adult men and women nursing home residents;
  • Confirmed diagnosis of CIC using Rome criteria;
  • Prescribed two or more laxatives, at recruitment;
  • Taking 9 or more oral medicines (including prescription, OTC and prn)
  • Free from conditions likely to be fatal within six months;
  • Able to read or understand English; and
  • Able and willing to provide informed consent or has a guardian/agent who can provide consent.

You may not qualify if:

  • Currently pregnant;
  • Presence of megacolon;
  • Presence of rectal sigmoid cancer;
  • Presence of colon cancer;
  • Presence of anal incompetence;
  • Conditions likely to be fatal within six months;
  • Taking 8 or fewer medicines;
  • Enrolled in hospice;
  • Non-English speaking patients; and
  • Unwilling or unable to provide informed consent and has no guardian/agent.
  • Expected to be discharged within 3 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Geriatric Medical Associates

Brooksville, Florida, United States

Location

Cassellberry Family Practice

Casselberry, Florida, United States

Location

Osler Geriatrics

Melbourne, Florida, United States

Location

MeSH Terms

Conditions

Constipation

Condition Hierarchy (Ancestors)

Signs and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Malcolm R Fraser, MD

    Synergy Health Solutions

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 24, 2009

First Posted

September 28, 2009

Study Start

November 1, 2009

Primary Completion

April 1, 2010

Study Completion

November 1, 2010

Last Updated

November 23, 2010

Record last verified: 2010-11

Locations